Form 4: BiomX CFO Marina Wolfson Reports Stock and Options Grants

Marina Wolfson, CFO of BiomX Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On April 14, 2025, Marina Wolfson, the Chief Financial Officer of BiomX Inc., reported transactions related to the company's stock.
• Wolfson acquired 68,545 Restricted Stock Units (RSUs) that are immediately vested and convert into common stock on a one-for-one basis.
• Additionally, Wolfson acquired options to purchase 95,000 shares of common stock at an exercise price of $0.538.
• These options vest over four years, starting with 25% vesting on April 14, 2026, and the remainder vesting in 12 equal quarterly installments over three years.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices. The grants align the CFO's interests with shareholders.

Positives

• The grant of RSUs and options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule for the options incentivizes long-term commitment from the CFO.

Industry Context

Stock option and RSU grants are common practice to incentivize and retain key executives in biotech companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron routinely grant stock options and RSUs to their executives.
• The vesting schedule of four years with a one-year cliff is also a common practice to ensure long-term commitment.

Stakeholder Impact

• The grants could have a slightly dilutive effect on existing shareholders.
• The grants incentivize the CFO to improve company performance, which benefits shareholders.

Key Dates

Keywords

BiomX, Wolfson, CFO, stock options, RSUs, Form 4, PHGE, equity compensation